References
- Frei E, Canellos G P. Dose, a critical factor in cancer chemotherapy. Am J Med 1980; 69: 585–594
- Takvorian T, Parker L M, Hochberg F H, Canellos G P. Autologous bone-marrow transplantation: host-effects of high dose BCNU. J Clin Oncol 1983; 1: 610–620
- Peters W P, Ross M, Vredenburgh J J, Meisenberg B, Marks L B, Winer E, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132–1143
- Ayash L J, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, et al. Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol 1990; 8: 1699–1706
- Stiff P J, Unger J M, Forman S J, McCall A R, LeBlanc M, Nademanee B J, et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003; 9: 529–539
- Puig N, de la Rubia J, Remigia M J, Jarque I, Martín G, Cupelli L, et al. Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma 2006; 47: 1488–1494
- Van Besien K W, Tabocoff J, Rodriguez M A, Andersson B, Mehra R, Przepiorka D, et al. Intensive chemotherapy with the BEAC regimen and autologous bone marrow transplantation in patients with refractory or recurrent intermediate grade and immunoblastic lymphoma; toxicity, long-term follow-up and identification of prognostic factors. Bone Marrow Transplant 1995; 15: 549–555